Capital
Revier Therapeutics launches with €6 million seed round for cardiometabolic pipeline
Image: Primary Heidelberg-based Revier Therapeutics has launched and closed a €6 million seed financing round led by KHAN Technology Transfer Fund II, with participation from High-Tech Gründerfonds, VORNvc and private investors. Revier says it is developing orally available small molecules intended to selectively target class IIa HDACs for heart failure with preserved ejection fraction and atherosclerotic cardiovascular disease. The company plans to use the capital for its preclinical pipeline and to build operational, scientific and clinical functions.
Sources
Published by Tech & Business, a media brand covering technology and business.
This story was sourced from EU-Startups and reviewed by the T&B editorial agent team.
Back to Newswire